MA49726B1 - Formulation d'anticorps anti-cgrp - Google Patents

Formulation d'anticorps anti-cgrp

Info

Publication number
MA49726B1
MA49726B1 MA49726A MA49726A MA49726B1 MA 49726 B1 MA49726 B1 MA 49726B1 MA 49726 A MA49726 A MA 49726A MA 49726 A MA49726 A MA 49726A MA 49726 B1 MA49726 B1 MA 49726B1
Authority
MA
Morocco
Prior art keywords
antibody formulation
cgrp antibody
headaches
episodic
chronic
Prior art date
Application number
MA49726A
Other languages
English (en)
Other versions
MA49726A (fr
Inventor
Anant N. SHARMA
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MA49726A publication Critical patent/MA49726A/fr
Publication of MA49726B1 publication Critical patent/MA49726B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des formulations pharmaceutiques d'anticorps anti-CGRP, et leurs procédés d'utilisation, lesdites formulations étant utiles dans le traitement des migraines, des maux de tête épisodiques, des maux de tête chroniques, des céphalées en grappe chroniques, et des céphalées en grappe épisodiques.
MA49726A 2015-06-17 2016-06-08 Formulation d'anticorps anti-cgrp MA49726B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562180905P 2015-06-17 2015-06-17
EP16729483.4A EP3310809B1 (fr) 2015-06-17 2016-06-08 Formulation d'anticorps anti-cgrp
PCT/US2016/036407 WO2016205037A1 (fr) 2015-06-17 2016-06-08 Formulation d'anticorps anti-cgrp

Publications (2)

Publication Number Publication Date
MA49726A MA49726A (fr) 2020-06-10
MA49726B1 true MA49726B1 (fr) 2025-02-28

Family

ID=56131672

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49726A MA49726B1 (fr) 2015-06-17 2016-06-08 Formulation d'anticorps anti-cgrp

Country Status (31)

Country Link
US (3) US11498959B2 (fr)
EP (2) EP4470557A3 (fr)
JP (1) JP6438599B2 (fr)
KR (1) KR102000867B1 (fr)
CN (3) CN114948847A (fr)
AR (2) AR104847A1 (fr)
AU (1) AU2016280555B2 (fr)
BR (1) BR112017023374A2 (fr)
CA (1) CA2984185A1 (fr)
DK (1) DK3310809T3 (fr)
EA (1) EA037580B1 (fr)
ES (1) ES3000607T3 (fr)
FI (1) FI3310809T3 (fr)
HR (1) HRP20241660T1 (fr)
HU (1) HUE069368T2 (fr)
IL (2) IL292562A (fr)
JO (1) JO3772B1 (fr)
LT (1) LT3310809T (fr)
MA (1) MA49726B1 (fr)
MD (1) MD3310809T2 (fr)
MX (1) MX395147B (fr)
MY (1) MY184266A (fr)
NZ (1) NZ737046A (fr)
PL (1) PL3310809T3 (fr)
PT (1) PT3310809T (fr)
RS (1) RS66243B1 (fr)
SI (1) SI3310809T1 (fr)
TW (1) TWI725973B (fr)
UA (1) UA120881C2 (fr)
WO (1) WO2016205037A1 (fr)
ZA (1) ZA201707324B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
EA201990548A1 (ru) * 2016-09-23 2019-09-30 Тева Фармасьютикалз Интернэшнл Гмбх Лечение кластерной головной боли
RU2770066C2 (ru) 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
JP7840636B2 (ja) * 2018-04-02 2026-04-06 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用
WO2019231800A1 (fr) * 2018-05-31 2019-12-05 Eli Lilly And Company Anticorps anti-cgrp pour le traitement des migraines liées aux menstruations
EA202190815A1 (ru) * 2018-09-20 2021-07-02 Тева Фармасьютикалз Интернэшнл Гмбх Инъекторная пружина для состаренного, предварительно заполненного шприца и автоинъектор
WO2020146527A1 (fr) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
KR20220004053A (ko) * 2019-05-02 2022-01-11 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 두통의 치료
CA3077973A1 (fr) 2020-04-06 2021-10-06 H. Lundbeck A/S Traitement du symptome le plus perturbant associe a la migraine au moyen d`anticorps anti-cgrp
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124690C (fr) 1992-10-02 2007-09-11 Thomas Osterberg Composition contenant une preparation du facteur de coagulation viii, methode de preparation et utilisation d'un surfactant comme stabilisateur
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
DK2236154T3 (en) 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
ES2569409T3 (es) * 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
WO2007142667A2 (fr) * 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Procédés et compositions destinées au traitement de patients atteints de maladies positives pour des auto-anticorps
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
EP3069731A1 (fr) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonistes d'anticorps dirigés contre un peptide associé au gène de la calcitonine et procédés les utilisant
WO2007123765A2 (fr) 2006-03-31 2007-11-01 Human Genome Sciences Inc. NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
CL2007003583A1 (es) 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
CA2674608A1 (fr) * 2007-01-09 2008-07-17 Wyeth Preparations d'anticorps ant-il-13 et leurs utilisations
EP2136839A4 (fr) * 2007-03-22 2010-04-07 Imclone Llc Formulations d'anticorps stables
CA2682292A1 (fr) 2007-03-30 2008-10-09 Medimmune, Llc Formulation aqueuse comportant un anticorps anti-interferon alpha humain
US20080292625A1 (en) * 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
PT2331090T (pt) * 2008-09-19 2018-02-07 Pfizer Formulação de anticorpo líquida estável
CA2738243C (fr) 2008-10-29 2020-09-29 Wyeth Llc Formulations de molecules de liaison d'antigene monodomaines
JP5933975B2 (ja) * 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
CN107913396B (zh) * 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
PT2691112T (pt) * 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
PE20141787A1 (es) * 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
PE20141545A1 (es) 2011-10-24 2014-11-26 Abbvie Inc Inmunoenlazadores dirigidos contra el tnf
WO2014031718A1 (fr) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Formulations stables d'anticorps contre la tslp
BR112015017619A2 (pt) * 2013-01-24 2017-11-21 Glaxosmithkline Ip Dev Ltd formulação líquida, uso de uma formulação, e, kit
AU2015230933B2 (en) * 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
BR112018007214A2 (pt) * 2015-10-30 2018-10-16 Lilly Co Eli anticorpos biespecíficos anti-cgrp/anti-il-23 e usos destes

Also Published As

Publication number Publication date
JP6438599B2 (ja) 2018-12-19
CN107787229A (zh) 2018-03-09
WO2016205037A1 (fr) 2016-12-22
HRP20241660T1 (hr) 2025-02-14
EP3310809B1 (fr) 2024-10-16
EA037580B1 (ru) 2021-04-16
MA49726A (fr) 2020-06-10
MY184266A (en) 2021-03-30
AR104847A1 (es) 2017-08-16
ES3000607T3 (en) 2025-03-03
MD3310809T2 (ro) 2025-03-31
CN118356393A (zh) 2024-07-19
CA2984185A1 (fr) 2016-12-22
MX2017016199A (es) 2018-03-01
US20220112277A1 (en) 2022-04-14
SI3310809T1 (sl) 2025-03-31
EP3310809A1 (fr) 2018-04-25
PL3310809T3 (pl) 2025-01-27
US20180134772A1 (en) 2018-05-17
HK1245813A1 (en) 2018-08-31
JO3772B1 (ar) 2021-01-31
ZA201707324B (en) 2020-01-29
MX395147B (es) 2025-03-24
AU2016280555A1 (en) 2017-11-16
CN114948847A (zh) 2022-08-30
IL255443A0 (en) 2017-12-31
AU2016280555B2 (en) 2018-11-15
EP4470557A2 (fr) 2024-12-04
IL292562A (en) 2022-06-01
TW201711697A (zh) 2017-04-01
JP2018517727A (ja) 2018-07-05
LT3310809T (lt) 2025-01-10
RS66243B1 (sr) 2024-12-31
TWI725973B (zh) 2021-05-01
US11498959B2 (en) 2022-11-15
IL255443B (en) 2022-06-01
EP4470557A3 (fr) 2025-02-26
US20230159628A1 (en) 2023-05-25
BR112017023374A2 (pt) 2018-07-24
UA120881C2 (uk) 2020-02-25
AR133453A2 (es) 2025-10-01
NZ737046A (en) 2019-09-27
KR20180002858A (ko) 2018-01-08
HUE069368T2 (hu) 2025-02-28
FI3310809T3 (fi) 2024-12-07
EA201792359A1 (ru) 2018-05-31
PT3310809T (pt) 2024-12-16
KR102000867B1 (ko) 2019-07-16
DK3310809T3 (da) 2024-12-02

Similar Documents

Publication Publication Date Title
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
MA46770A (fr) Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA40682B1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MX381232B (es) Formulación de anticuerpos.
EA201792616A1 (ru) Средства, пути применения и способы лечения синуклеопатии
MA40576A (fr) Anticorps et immunoconjugués anti-her2
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
MA38554A3 (fr) Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation
EA201792182A1 (ru) Композиции и способы для лечения анемии
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201592203A1 (ru) Способы лечения таупатии
EP2968470A4 (fr) Protéines de substance d'inhibition mullerienne (mis) modifiées et leurs utilisations pour le traitement de maladies